Lara D. Veeken · 2020 · 40 citations · 14 references
MedicineImmunologyInfectious DiseasesClinical EpidemiologyEpidemiologyImmunopathologyJuvenile DermatomyositisJuvenile Idiopathic ArthritisAutoimmune MyositisInfection Risk FactorsInfectious MyopathiesMyositis-associated AutoantibodiesMyositis-specific AutoantibodiesNatural History Studies Of Rare DiseasesPathogenic AutoantibodiesPneumonia Diagnosis
OBJECTIVES: Pneumocystis jirovecii pneumonia (PJP) is associated with significant morbidity and mortality in adult myositis patients; however, there are few studies examining PJP in juvenile myositis [juvenile idiopathic inflammatory myopathy (JIIM)]. The purpose of this study was to determine the risk factors and clinical phenotypes associated with PJP in JIIM. METHODS: An research electronic data capture (REDCap) questionnaire regarding myositis features, disease course, medications and PJP infection characteristics was completed by treating physicians for 13 JIIM patients who developed PJP (PJP+) from the USA and Canada. Myositis features and medications were compared with 147 JIIM patients without PJP (PJP-) from similar geographic regions who enrolled in National Institutes of Health natural history studies. RESULTS: PJP+ patients were more often of Asian ancestry than PJP- patients [odds ratio (OR) 8.7; 95% CI 1.3, 57.9]. Anti- melanoma differentiation associated protein 5 (MDA5) autoantibodies (OR 12.5; 95% CI 3.0, 52.4), digital infarcts (OR 43.8; 95% CI 4.2, 460.2), skin ulcerations (OR 12.0; 95% CI 3.5, 41.2) and interstitial lung disease (OR 10.6; 95% CI 2.1, 53.9) were more frequent in PJP+ patients. Before PJP diagnosis, patients more frequently received pulse steroids, rituximab and more immunosuppressive therapy compared with PJP- patients. Seven PJP+ patients were admitted to the intensive care unit and four patients died due to PJP or its complications. CONCLUSIONS: PJP is a severe infection in JIIM that can be associated with mortality. Having PJP was associated with more immunosuppressive therapy, anti-MDA5 autoantibodies, Asian race and certain clinical features, including digital infarcts, cutaneous ulcerations and interstitial lung disease. Prophylaxis for PJP should be considered in juvenile myositis patients with these features.
14
Paul A. Harris, Robert Taylor, Robert J. Thielke et al. · Journal of Biomedical Informatics · 2008 · 51.7K citations · Full text
The Myositis Autoantibody Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies
Lisa G. Rider, Mona Shah, Gulnara Mamyrova et al. · Medicine · 2013 · 294 citations · Full text
Opportunistic infections in polymyositis and dermatomyositis
I. Marie, É. Hachulla, P. Chérìn et al. · Arthritis Care & Research · 2005 · 171 citations
Adam M. Huber, Angela Byun Robinson, Ann M. Reed et al. · Arthritis Care & Research · 2011 · 130 citations
Medicine, Child Health, Pediatrics +13